Navigation Links
ADHD in Medical News

Queen's University study aims at early diagnosis for ADHD and Parkinson's disease

Eye movement tests developed by Queen's University researchers to aid in understanding childhood brain development and healthy aging may also help in the diagnosis of Attention Deficit Hyperactivity Disorder and detecting the early onset of Parkinson's disease. The project has received close to $1...

Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children

Consumers Could Save Roughly $3,000 A Year By Switching From Expensive Brand Name Drugs to Equally Effective Generics To Treat Attention Deficit Hyperactivity Disorder (ADHD) YONKERS, N.Y., July 8 /PRNewswire-USNewswire/ -- According to a new Consumer Reports Best Buy Drugs report, parents ...

Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms

San Francisco, CA May 18, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met i...

Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18

PHILADELPHIA, May 15 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (CII) and ...

Treating Sleep Disorders May Ease ADHD Symptoms

Team suggests screening spares patients lifetime of problems FRIDAY, May 1 (HealthDay News) -- Researchers say a lifetime of problems with getting a good night's sleep could be in store for any child diagnosed with attention-deficit hyperactivity disorder (ADHD). The study of 281 ch...

Meds Help Kids With ADHD in Classroom

Study finds they test higher than unmedicated peers in grade school MONDAY, April 27 (HealthDay News) -- Children who take medication to treat attention-deficit hyperactivity disorder (ADHD) do better in elementary school than those who don't, a new study has found. Of 594 children ...

Video: Adults 'Facing' ADHD: ADHD Allies(TM) Offers Unique Online Community for Adults with ADHD on New Facebook(R) Page

TITUSVILLE, N.J., April 22 /PRNewswire/ -- Although Attention Deficit Hyperactivity Disorder (ADHD) is a condition commonly thought of as only affecting children, for nearly 9 million adults in the United States, ADHD is very much a reality. According to the National Institutes of Mental Healt...

UCF study: Hyperactivity enables children with ADHD to stay alert

A new University of Central Florida study may explain why children with attention deficit hyperactivity disorder move around a lot it helps them stay alert enough to complete challenging tasks. In studies of 8- to 12-year-old boys, Psychology Professor Mark D. Rapport found that children with ...

Mouse Study Suggests ADHD Drug Might Be Addictive

But expert says finding doesn't apply to patients because doses used were so high TUESDAY, Feb. 3 (HealthDay News) -- Ritalin, a drug commonly used to treat children with attention-deficit hyperactivity disorder (ADHD), caused changes in the brain cells of mice similar to those seen wi...

Hallucinations Are Rare Side Effects of ADHD Medications

Visual or tactile sensations of bugs an uncommon, but possible, reaction, study finds,,,, MONDAY, Jan. 26 (HealthDay News) -- Children who take medications for attention-deficit hyperactivity disorder (ADHD) may rarely experience some disturbing side effects, such as hallucinations. ...

More>>

ADHD in Medical Technology

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). Thi...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PP...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

SAN FRANCISCO, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo con...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Cl...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in th...

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day

- Focalin XR demonstrated better symptom control versus Concerta from 30 minutes to six hours post-dose in primary and secondary endpoints - Only Focalin XR provided onset of effect as early as 30 minutes post-dose - Additional analysis suggests Focalin XR provides comparable efficacy to ...

Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists

VYVANSE demonstrated significant improvement in ADHD symptoms in adults WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated signif...

New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months

WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between ...

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investiga...

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting

PHILADELPHIA, May 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphen...
ADHD in Medical Definition

Neuropsychiatry

...e G protein receptor kinase 3 gene is associated with bipolar disorder. Molecular Psychiatry, 8, 546−557. Baughman, F.A., & Hovey, J. (2006) The adhd Fraud: How Psychiatry Makes "Patients" of Normal Children . Oxford, UK: Trafford Publishing. Becker, A.E. (2004) Television, Disordered Eating, and ...
ADHD in Medical Dictionary

ADHD

Attention-deficit HD) is a neurobehavioral developmental disorder. ADHD is primarily characterized by "the co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone." While... National Institute of Mental Health publication which descr...

Ritalin

...efinitive daily health, fitness, and lifestyle destination... Stimulant adhd Medications: Methylphenidate and Amphetamines information at the ... methyl...wly but as ... Ritalin is the most commonly prescribed medication for adhd (attention deficit ... So what are the benefits of Ritalin , and what are ...

Hyperactivity

...t HD) is a neurobehavioral developmental disorder. adhd is primarily characterized by "the co-existen...ms>What Is Hyperactivity ? ... People with adhd have differences in the parts of their brains that control ... adhd stands for attention deficit hyperactivity dis...

Hyperactivity Disorder

... Attention-deficit HD) is a neurobehavioral developmental disorder . adhd is primarily characterized by "the co-existence of attentional problems and hyperactivity , with each behavior occurring infrequently alone.&q...

Attention-deficit hyperactivity disorder

... Attention - deficit HD) is a neurobehavioral developmental disorder . adhd is primarily characterized by "the co-existence of attentional problem...n Deficit Disorder . SYMPTOMS ... Attention Deficit Screening Quiz. adhd Treatment ... Find the latest news stories, overviews, research and mor...

Attention-Deficit

... HD) is a neurobehavioral developmental disorder. adhd is primarily characterized by "the co-existen...order (ADHD) is a common childhood behavioral ... adhd used to be known as attention deficit disorder, or ADD. ... adhd prevalence, assessment, and treatment ... Atten...

Attention deficit disorder

...HD) is a neurobehavioral developmental disorder . adhd is primarily characterized by "the co-existen...SYMPTOMS ... Attention Deficit Screening Quiz. adhd Treatment ... ... attention deficit disor...Disorder . The Survival Guide for Kids With ADD or adhd ... More about Attention - Deficit /Hyperacti...

Attention deficit

... HD) is a neurobehavioral developmental disorder. adhd is primarily characterized by "the co-existen...cits, Attention Deficit Disorder, ADD-ADHD adhd prevalence, assessment, and treatment ... Atten...order (ADHD) is a common childhood behavioral ... adhd used to be known as attention deficit disorder...

ADD

... The FDA has added black-box warnings to some adhd ... In the DSM-III " ADD ( Attention-Def...ciation ... Living with ADD /ADHD. ADDults with adhd (Australian) ... informational guide to add /ad...d learning sisorders (LD) ... live with ADD , adhd and other disabilites and disorders and homeschool...
ADHD in Biological News

Did the gene for ADHD help our nomadic ancestors?

An ADHD-associated version of the human gene DRD4 is linked to better health among nomadic tribesmen, but may cause malnourishment in their settled cousins, according to new research by a team directed by an anthropologist at the University of Wisconsin-Milwaukee (UWM). A study by UWM assistant...

Adolescent girls with ADHD are at increased risk for eating disorders, study shows

Girls with attention deficit hyperactivity disorder stand a substantially greater risk of developing eating disorders in adolescence than girls without ADHD, a new study has found. "Adolescent girls with ADHD frequently develop body-image dissatisfaction and may go through repeating cycles of b...

Effective ADHD treatment found for children with fragile X syndrome

Fragile X syndrome (FXS) is the most common hereditary form of mental retardation. Many children with FXS also suffer from attention deficit and/or hyperactivity disorder (ADHD), which complicates social relationships at home and at school. Although stimulant medication such as Ritalin is often su...

Ohio scientists develop blue-blocking glasses to improve sleep and ADHD symptoms

Scientists at John Carroll University, working in its Lighting Innovations Institute, have developed an affordable accessory that appears to reduce the symptoms of ADHD. Their discovery also has also been shown to improve sleep patterns among people who have difficulty falling asleep. The John Ca...

Studies examine genetic determinants of ADHD

Boston, Mass. January 07, 2009 A special issue of American Journal of Medical Genetics (AJMG): Part B: Neuropsychiatric Genetics presents a comprehensive overview of the latest progress in genetic research of Attention Deficit/Hyperactivity Disorder (ADHD). The issue covers major trends in the...

Study reveals how ADHD drugs work in brain

Although millions depend on medications such as Ritalin to quell symptoms of attention deficit hyperactivity disorder (ADHD), scientists have struggled to pinpoint how the drugs work in the brain. But new work at the University of Wisconsin-Madison is now starting to clear up some of the mystery...

22nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey

...topics to be presented by more than 600 experts , and will comprise, among others, the following topics: The role of genetic factors in adult adhd The future of schizophrenia Are the monoamines involved in shaping conduct disorder? Vaccination for Alzheimers disease in dementia Novel tr...

22nd Congress of the European College of Neuropsychopharmacology

... The scientific programme will comprise, among others, the following topics: The future of schizophrenia The role of genetic factors in adult adhd Is the monoamines involved in shaping conduct disorder? Vaccination for Alzheimers disease in dementia Novel treatment for smoking Maternal s...

Fetal alcohol syndrome testing expands

...unctional MRI (magnetic resonance imaging) facility to measure differences in brain activity in children with developmental disorders such as FASD and adhd (Attention Deficit Hyperactivity Disorder). They are building a database of task performance and brain functioning across many clinical populations. ...

M.I.N.D. Institute researchers call for fragile X testing throughout the lifespan

...milies," she said. Research by the Hagermans and others has shown that mutations of the fragile X gene can cause, among other disorders, autism and adhd in children, anxiety disorders at all ages, early menopause in women and dementia in the elderly. Because the potential impact is so great, M.I.N.D...
ADHD in Biological Technology

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-dai...

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment

VYVANSE is the first stimulant to establish duration of efficacy from two hours up to 14 hours after administration in adults with ADHD HOLLYWOOD, Fla., July 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced res...

Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL

PHILADELPHIA and DUBLIN, February 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM(R) IR and XL (methylphenidate hydrochloride) (exc...

FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults

CONCERTA(R) now available for patients with ADHD ages 6 to 65 RARITAN, N.J., June 27 /PRNewswire/ -- ADHD is the most common emotional, cognitive and behavioral disorder treated in children(1), and according to the National Institute of Mental Health (NIMH), between 30 percent and 70 perc...

Shire Launches Nationwide Adult ADHD Mobile Awareness Tour

ADHD screening initiative launches in Atlanta and continues for 90 days; Shire expects up to 20,000 adults to self-screen for ADHD in 13 cities across the country PHILADELPHIA, May 12 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global special...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

Within the First Eight Months Since its Introduction in the United States, VYVANSE has Achieved Over One Million Prescriptions In a Clinical Study With Adults, VYVANSE was Shown to Significantly Improve the Symptoms of ADHD (Inattention, Hyperactivity and Impulsivity)(1) BASINGSTOKE, ...

FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients

To Date, More than 500,000 Total Prescriptions Have Been Dispensed for VYVANSE 30, 50 and 70 mg PHILADELPHIA, Jan. 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced that it has rece...

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

ADHD symptom control demonstrated from the first time point measured (1.5 hours) through 13 hours postdose PHILADELPHIA, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced that the US Food and Drug Adminis...

Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD

PHILADELPHIA, March 31 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today announced a co-promotion agreement with GlaxoSmithKline plc (NYSE: GSK ) for VYVANSE(R) (lisdexamfetamine dimesylate) capsules CII with the aim of im...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...im of improving recognition and treatment of adhd in adults. - On June 1, 2009 Shire announced ...plemental data that demonstrated significant adhd symptom control in children aged 6 to 12 fro... post-dose. VYVANSE is now the first and only oral adhd stimulant treatment to have 13 hour post-dos...
Other Tags
(Date:7/24/2014)... of Association Executives (ASAE) announced its 2014 Power of ... American Society of Anesthesiologists (ASA). , The ASA ... A Gold Award, one of the top honors from ... of the world through education on the global anesthesia ... care. , ASA was also honored with a Power ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 ... leading specialist in hematology and oncology, Dr. Hitendra ... Group. Our system welcomes Dr. Upadhyaya to the ... comprise CarePoint Health Medical Group, a comprehensive network ... representing a wide range of specialties. This latest ...
(Date:7/24/2014)... Kathleen Doheny HealthDay Reporter ... obese children often don,t view their kids as unhealthy or ... to a new study. The children of the families ... at the Hasbro Children,s Hospital in Providence, R.I. "A ... said study researcher Dr. Kyung Rhee, now an assistant professor ...
(Date:7/24/2014)... head and neck cancer (HNC). Evidence suggests certain cancers are ... HNC in patients with DM has not been well explored. ... type of cancer. It accounts for about 6 percent of ... and 350,000 cancer deaths worldwide each year. , The authors ... risk of HNC in patients with DM. The authors compared ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Pools and beaches ... the water can be dangerous, especially for small children, so ... water safety. , According to the Centers for Disease Control ... are most at risk for water-related injuries and deaths. It’s ... safe around water, so Amica is offering the following tips ...
Breaking Medicine News(10 mins):Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... how wildlife loss leads to conflict among people around ... Conservation Society (WCS) Health & Ecosystems: Analysis of Linkages ... interdisciplinary approach to tackle global biodiversity decline. , The ... the world,s people and provides protein for more than ... as no surprise that today,s unprecedented loss of wildlife, ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
Other Contents